Ensign Peak Advisors, Inc C4 Therapeutics, Inc. Transaction History

Ensign Peak Advisors, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $37,500 - $59,635	4,670 Added 182.42%	7,230 $63,000
Q2 2022 Aug 12, 2022	SELL	$5.06 - $26.46 $130,512 - $682,482	-25,793 Reduced 90.97%	2,560 $19,000
Q4 2021 Feb 11, 2022	BUY	$29.39 - $46.86 $75,238 - $119,961	2,560 Added 9.93%	28,353 $913,000
Q3 2021 Nov 12, 2021	SELL	$35.91 - $50.5 $510,173 - $717,453	-14,207 Reduced 35.52%	25,793 $1.15 Million
Q4 2020 Feb 12, 2021	BUY	$22.8 - $37.05 $912,000 - $1.48 Million	40,000 New	40,000 $1.33 Million

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $208M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.